Ann: Invex Granted Type C Meeting with FDA, page-16

IMO, it's positive that a Type C meeting was granted and neutral-positive that IXC requested a Type B and were granted a Type C.

I'm leaning towards this being great news for the reasons outlined by @jellyroll. I don't necessarily agree that WRO is a bad thing in the current climate. It could very well mean that this is a straightforward case, given the Type 2 data, detailed statistical plan and EMA advice. Thus, IXC may only require written responses without additional guidance.

I also think the share price has factored in much of the worst case scenario - i.e., two trials are required by the FDA. I don't expect the SP to touch $0.40, but I guess anything is possible. Nothing about the market makes sense today.

@ralom - agree that it's frustrating, but we'll soon find out the reasons for the delay. This quarter is going to be a big one.